Clinical impact of computed tomography-measured skeletal muscle status at the third cervical vertebra on definitive radiotherapy outcomes for head and neck squamous cell carcinoma.
{"title":"Clinical impact of computed tomography-measured skeletal muscle status at the third cervical vertebra on definitive radiotherapy outcomes for head and neck squamous cell carcinoma.","authors":"Yuki Kasuga, Atsuto Katano, Masanari Minamitani, Shouhei Hanaoka, Shin Fujiwara, Yuki Saito, Koji Yamamura, Kenya Kobayashi, Hideomi Yamashita, Osamu Abe, Wataru Gonoi","doi":"10.1007/s11604-025-01888-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Loss of skeletal muscle mass is increasingly recognized as a poor prognostic indicator in patients with cancer, including those with head and neck squamous cell carcinoma (HNSCC). Emerging evidence suggests that the muscle area measured at the third cervical vertebra (C3) on CT serves as a practical surrogate for whole-body muscle status. This study aimed to evaluate the prognostic significance of C3-level body composition parameters in patients with HNSCC undergoing definitive radiotherapy.</p><p><strong>Materials and methods: </strong>A total of 283 consecutive patients with HNSCC treated with definitive radiotherapy between 2013 and 2023 were retrospectively analyzed. Pre-treatment CT scans were used to assess six body composition metrics at the C3 level: skeletal muscle area (SMA), mean skeletal muscle density, visceral adipose tissue area, subcutaneous adipose tissue area, visceral-to-subcutaneous fat ratio, and skeletal muscle fat infiltration index. Patients were stratified into high and low groups based on sex-specific median values. Associations between each body composition metric (high vs. low) and survival outcomes were assessed using univariate and multivariate analyses.</p><p><strong>Results: </strong>The cohort included 238 males and 45 females, with a median age of 67 years. Survival analysis showed a median follow-up period of 39.3 months. The 3-year overall survival (OS) rate for the entire cohort was 81.6%, and the 3-year progression free survival rate was 60.8%. In univariate analysis, only low SMA was significantly associated with poorer OS (hazard ratio: 1.841, p = 0.027). The median SMA was 35.0 cm<sup>2</sup> for males and 23.5 cm<sup>2</sup> for females. In multivariate analysis, low SMA remained an independent predictor of reduced OS (hazard ratio: 1.851, p = 0.028), along with clinical stage and chemotherapy status.</p><p><strong>Conclusion: </strong>Among the CT-derived body composition parameters assessed at the C3 level, low SMA was the only significant independent predictor of OS in patients with HNSCC receiving definitive radiotherapy. These findings support the clinical relevance of SMA assessment as a straightforward and robust prognostic biomarker and underscore the need for further investigation into the prognostic potential of other body composition metrics.</p>","PeriodicalId":14691,"journal":{"name":"Japanese Journal of Radiology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11604-025-01888-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background and purpose: Loss of skeletal muscle mass is increasingly recognized as a poor prognostic indicator in patients with cancer, including those with head and neck squamous cell carcinoma (HNSCC). Emerging evidence suggests that the muscle area measured at the third cervical vertebra (C3) on CT serves as a practical surrogate for whole-body muscle status. This study aimed to evaluate the prognostic significance of C3-level body composition parameters in patients with HNSCC undergoing definitive radiotherapy.
Materials and methods: A total of 283 consecutive patients with HNSCC treated with definitive radiotherapy between 2013 and 2023 were retrospectively analyzed. Pre-treatment CT scans were used to assess six body composition metrics at the C3 level: skeletal muscle area (SMA), mean skeletal muscle density, visceral adipose tissue area, subcutaneous adipose tissue area, visceral-to-subcutaneous fat ratio, and skeletal muscle fat infiltration index. Patients were stratified into high and low groups based on sex-specific median values. Associations between each body composition metric (high vs. low) and survival outcomes were assessed using univariate and multivariate analyses.
Results: The cohort included 238 males and 45 females, with a median age of 67 years. Survival analysis showed a median follow-up period of 39.3 months. The 3-year overall survival (OS) rate for the entire cohort was 81.6%, and the 3-year progression free survival rate was 60.8%. In univariate analysis, only low SMA was significantly associated with poorer OS (hazard ratio: 1.841, p = 0.027). The median SMA was 35.0 cm2 for males and 23.5 cm2 for females. In multivariate analysis, low SMA remained an independent predictor of reduced OS (hazard ratio: 1.851, p = 0.028), along with clinical stage and chemotherapy status.
Conclusion: Among the CT-derived body composition parameters assessed at the C3 level, low SMA was the only significant independent predictor of OS in patients with HNSCC receiving definitive radiotherapy. These findings support the clinical relevance of SMA assessment as a straightforward and robust prognostic biomarker and underscore the need for further investigation into the prognostic potential of other body composition metrics.
期刊介绍:
Japanese Journal of Radiology is a peer-reviewed journal, officially published by the Japan Radiological Society. The main purpose of the journal is to provide a forum for the publication of papers documenting recent advances and new developments in the field of radiology in medicine and biology. The scope of Japanese Journal of Radiology encompasses but is not restricted to diagnostic radiology, interventional radiology, radiation oncology, nuclear medicine, radiation physics, and radiation biology. Additionally, the journal covers technical and industrial innovations. The journal welcomes original articles, technical notes, review articles, pictorial essays and letters to the editor. The journal also provides announcements from the boards and the committees of the society. Membership in the Japan Radiological Society is not a prerequisite for submission. Contributions are welcomed from all parts of the world.